[go: up one dir, main page]

WO2008152792A1 - 骨粗鬆症感受性遺伝子、及び骨粗鬆症罹患リスクの測定方法 - Google Patents

骨粗鬆症感受性遺伝子、及び骨粗鬆症罹患リスクの測定方法 Download PDF

Info

Publication number
WO2008152792A1
WO2008152792A1 PCT/JP2008/001453 JP2008001453W WO2008152792A1 WO 2008152792 A1 WO2008152792 A1 WO 2008152792A1 JP 2008001453 W JP2008001453 W JP 2008001453W WO 2008152792 A1 WO2008152792 A1 WO 2008152792A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
osteoporosis
suffering
risk
determination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001453
Other languages
English (en)
French (fr)
Inventor
Satoshi Inoue
Tomohiko Urano
Yasuyoshi Ouchi
Masataka Shiraki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of WO2008152792A1 publication Critical patent/WO2008152792A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

骨粗鬆症感受性遺伝子、骨粗鬆症の発症リスクを判定する方法、及び骨粗鬆症発症リスクを有する者に投与することを特徴とする医薬を提供する。この判定方法に使用される骨粗鬆症罹患リスク診断マーカー、プローブ、プライマー並びに試薬キットを提供する。 【解決手段】骨粗鬆症感受性遺伝子として、ヒトのＳＭＡＤ６遺伝子、TGFβR１遺伝子、Ｓｙｎｔａｘｉｎ１８遺伝子、ＷＤＳＯＦ１の遺伝子、ＡＤＡＭＴＳ１遺伝子、ＦＡＭ５Ｃ遺伝子近傍、ＧＰＲ９８遺伝子近傍、ＧＰＲ９８遺伝子、ＳＬＣ２５Ａ３２遺伝子、ＣＴＨＲＣ１遺伝子近傍、ＣＴＨＲＣ１遺伝子、又はＦＤＺ６遺伝子に存在する遺伝子多型を提供する。また、骨粗鬆症の発症リスクのある者を特定する手段を含む骨粗鬆症薬キットとする。  
PCT/JP2008/001453 2007-06-08 2008-06-06 骨粗鬆症感受性遺伝子、及び骨粗鬆症罹患リスクの測定方法 Ceased WO2008152792A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-153035 2007-06-08
JP2007153035A JP5396009B2 (ja) 2007-06-08 2007-06-08 骨粗鬆症感受性遺伝子、及び骨粗鬆症罹患リスクの測定方法

Publications (1)

Publication Number Publication Date
WO2008152792A1 true WO2008152792A1 (ja) 2008-12-18

Family

ID=40129407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001453 Ceased WO2008152792A1 (ja) 2007-06-08 2008-06-06 骨粗鬆症感受性遺伝子、及び骨粗鬆症罹患リスクの測定方法

Country Status (2)

Country Link
JP (1) JP5396009B2 (ja)
WO (1) WO2008152792A1 (ja)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508835A (ja) * 2000-09-14 2004-03-25 デコード　ジェネティクス　イーエッチエフ． ヒト骨粗鬆症遺伝子
JP2006014738A (ja) * 2004-06-29 2006-01-19 F Hoffmann La Roche Ag 骨粗鬆症と、ＰＰＡＲγ中の一塩基多型との相関関係
JP2006034209A (ja) * 2004-07-29 2006-02-09 Japan Clinical Laboratories Inc Ｕｇｔ１ａ３核酸配列の変異検査方法
WO2006014013A1 (ja) * 2004-08-04 2006-02-09 Riken 骨・関節疾患感受性遺伝子およびその用途
JP2006042735A (ja) * 2004-08-06 2006-02-16 Institute Of Physical & Chemical Research 骨・関節疾患感受性遺伝子およびその用途
JP2006061090A (ja) * 2004-08-27 2006-03-09 Nipro Corp 骨密度予測方法および遺伝子多型分析用試薬キット

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508835A (ja) * 2000-09-14 2004-03-25 デコード　ジェネティクス　イーエッチエフ． ヒト骨粗鬆症遺伝子
JP2006014738A (ja) * 2004-06-29 2006-01-19 F Hoffmann La Roche Ag 骨粗鬆症と、ＰＰＡＲγ中の一塩基多型との相関関係
JP2006034209A (ja) * 2004-07-29 2006-02-09 Japan Clinical Laboratories Inc Ｕｇｔ１ａ３核酸配列の変異検査方法
WO2006014013A1 (ja) * 2004-08-04 2006-02-09 Riken 骨・関節疾患感受性遺伝子およびその用途
JP2006042735A (ja) * 2004-08-06 2006-02-16 Institute Of Physical & Chemical Research 骨・関節疾患感受性遺伝子およびその用途
JP2006061090A (ja) * 2004-08-27 2006-03-09 Nipro Corp 骨密度予測方法および遺伝子多型分析用試薬キット

Also Published As

Publication number Publication date
JP2008301777A (ja) 2008-12-18
JP5396009B2 (ja) 2014-01-22

Similar Documents

Publication Publication Date Title
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006050475A3 (en) Identification of dysregulated genes in patients with neurological diseases
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008150496A3 (en) Assay for sensitivity to chemotherapeutic agents
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2009059321A3 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
EP2071025A4 (en) PRIMER SET FOR THE REINFORCEMENT OF THE UGT1A1 GENE, REAGENT FOR THE REINFORCEMENT OF THE UGT1A1 GENE THEREFOR AND APPLICATION THEREOF
HUP0400904A2 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
WO2007145992A3 (en) Genetic basis of treatment response in depression patients
WO2009057294A1 (ja) 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2009152484A3 (en) Methods and platforms for drug discovery
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
HK1201605A1 (en) Personalized strategic cancer treatment
EP2857522A3 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
EP2249155A3 (en) Cancer markers
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
WO2009089277A3 (en) Rel inhibitors and methods of use thereof
WO2007058968A3 (en) Gene expression profiles and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764050

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08764050

Country of ref document: EP

Kind code of ref document: A1